Linda Shu

Linda Shu is a figure connected to the burgeoning field of Chinese AI-driven drug-design companies that are increasingly engaging in global out-licensing deals. These firms have seen a dramatic rise in deal values, reaching an estimated US$75 billion in the first five months of 2026, a significant increase from pre-2020 levels. This expansion is occurring despite heightened scrutiny from Washington on Chinese biotech companies. The context for this global push includes challenges faced by Chinese medical device makers, such as an anti-corruption squeeze and a 12% year-on-year fall in government-backed hospital purchases in the first five months of 2026. While the articles do not explicitly detail Linda Shu's specific role, her mention is linked to the broader trend of Chinese innovative companies, particularly in the biotech and medical device sectors, seeking international markets and partnerships amidst domestic regulatory pressures and growing global trade protectionism. The current relevance lies in the significant financial growth and international ambition of China's AI drug-design sector.